Cardiac allograft vasculopathy prevention: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Cardiac Allograft Vasculopathy}} {{CMG}}; {{AE}} {{AN}} {{RT}} ==Overview== ==Prevention== ==References== {{reflist|2}} {{WH}} {{WS}}") |
|||
| Line 6: | Line 6: | ||
==Prevention== | ==Prevention== | ||
As the pathogenesis of CAV consists of both immunological and non-immunological insults, preventative strategies should consist of control of risk factors for CAV and optimal [[immunosuppressive therapy]]. | |||
===Optimization of Immunosuppressive Therapy=== | |||
Options for immunosuppressive therapy for prevention of CAV includes: | |||
* [[Immunosuppressive drugs#Drugs Acting on Immunophilins|Calcineurin inhibitors]], such as | |||
** [[Cyclosporine]] | |||
** [[Tacrolimus]] | |||
* [[Rapamycin]] derivatives, such as | |||
** [[Sirolimus]] | |||
** [[Everolimus]] | |||
* [[Corticosteroids]] | |||
* [[Azathioprine]] | |||
* [[Mycophenolate mofetil]] | |||
==References== | ==References== | ||
Revision as of 19:22, 1 October 2014
Template:Cardiac Allograft Vasculopathy Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2] Raviteja Guddeti, M.B.B.S. [3]
Overview
Prevention
As the pathogenesis of CAV consists of both immunological and non-immunological insults, preventative strategies should consist of control of risk factors for CAV and optimal immunosuppressive therapy.
Optimization of Immunosuppressive Therapy
Options for immunosuppressive therapy for prevention of CAV includes:
- Calcineurin inhibitors, such as
- Rapamycin derivatives, such as
- Corticosteroids
- Azathioprine
- Mycophenolate mofetil